Gamma-MSH/MC3R natriuretic signaling system: The possible explanation for contrasting blood pressure effects of agouti mutation and melanocortin receptor knockout

Bioscience Hypotheses

Volumn 1, Issue 5, 2008, Pages 243-247

  Bełtowski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Agouti protein; Arterial hypertension; Leptin; Melanocortins; Obesity

Indexed keywords

AGOUTI PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOBESITY AGENT; GAMMA INTERMEDIN; LEPTIN; MELANOCORTIN; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 3 RECEPTOR AGONIST; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN 4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; HORMONE BINDING; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERPHAGIA; HYPERTENSION; HYPOTHALAMUS; NATRIURESIS; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK FACTOR; RODENT; SIGNAL TRANSDUCTION;

AGOUTI; ANIMALIA; MUS; RODENTIA;

EID: 58149108950     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2008.07.007     Document Type: Article

References (45)

1. Yang R., and Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ Res 101 (2007) 545-559
2. Bełtowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 24 (2006) 789-801
3. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
4. Agata J., Masuda A., Takada M., Higashiura K., Murakami H., Miyazaki Y., et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10 (1997) 1171-1174
5. Shek E.W., Brands M.W., and Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 31 (1998) 409-414
6. Aizawa-Abe M., Ogawa Y., Masuzaki H., Ebihara K., Satoh N., Iwai H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (2000) 1243-1252
7. Mark A.L., Shaffer R.A., Correia M.L., Morgan D.A., Sigmund C.D., and Haynes W.G. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 17 (1999) 1949-1953
8. Tallam L.S., da Silva A.A., and Hall J.E. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension 48 (2006) 58-64
9. Oswal A., and Yeo G.S. The leptin melanocortin pathway and the control of body weight: lessons from human and murine genetics. Obes Rev 8 (2007) 293-306
10. Coll A.P. Effects of pro-opiomelanocortin (POMC) on food intake and body weight: mechanisms and therapeutic potential?. Clin Sci 113 (2007) 171-182
11. Hâkansson M.L., Brown H., Ghilardi N., Skoda R.C., and Meister B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J Neurosci 18 (1998) 559-572
12. Elias C.F., Aschkenasi C., Lee C., Aschkenasi C., Ahima R.S., Couceyro P.R., et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23 (1999) 775-786
13. Haynes W.G., Morgan D.A., Djalali A., Sivitz W.I., and Mark A.L. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 33 (1999) 542-547
14. da Silva A.A., Kuo J.J., and Hall J.E. Role of hypothalamic melanocortin 3/4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 43 (2004) 1312-1317
15. Rahmouni K., Haynes W.G., Morgan D.A., and Mark A.L. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosci 23 (2003) 5998-6004
16. Kuo J.J., Silva A.A., and Hall J.E. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 41 (2003) 768-774
17. Tallam L.S., Stec D.E., Willis M.A., da Silva A.A., and Hall J.E. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 46 (2005) 326-332
18. da Silva A.A., do Carmo J.M., Kanyicska B., Dubinion J., Brandon E., and Hall J.E. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 51 (2008) 884-890
19. Kim J.H., Kiefer L.L., Woychik R.P., Wilkison W.O., Truesdale A., Ittoop O., et al. Agouti regulation of intracellular calcium: role of melanocortin receptors. Am J Physiol 272 (1997) E379-E384
20. Tallam L.S., Kuo J.J., da Silva A.A., and Hall J.E. Cardiovascular, renal, and metabolic responses to chronic central administration of agouti-related peptide. Hypertension 44 (2004) 853-858
21. Hwang L.L., Chen C.T., Li T.L., Chiu C.Z., and Chi S.F. Central pressor effects of CART peptides in anesthetized rats. Neuropeptides 38 (2004) 69-76
22. Wikberg J.E., Muceniece R., Mandrika I., Prusis P., Lindblom J., Post C., et al. New aspects on the melanocortins and their receptors. Pharmacol Res 42 (2000) 393-420
23. Humphreys M.H. Cardiovascular and renal actions of melanocyte-stimulating hormone peptides. Curr Opin Nephrol Hypertens 16 (2007) 32-38
24. Lin S.Y., Chaves C., Wiedemann E., and Humphreys M.H. A gamma-melanocyte stimulating hormone-like peptide causes reflex natriuresis after acute unilateral nephrectomy. Hypertension 10 (1987) 619-627
25. Chen X.W., Ying W.Z., Valentin J.P., Ling K.T., Lin S.Y., Wiedemann E., et al. Mechanism of the natriuretic action of gamma-melanocyte-stimulating hormone. Am J Physiol 272 (1997) R1946-R1953
26. Mayan H., Ling K.T., Lee E.Y., Wiedemann E., Kalinyak J.E., and Humphreys M.H. Dietary sodium intake modulates pituitary proopiomelanocortin mRNA abundance. Hypertension 28 (1996) 244-249
27. Hao J., and Rabkin S.W. Differences in pituitary expression of proopiomelanocortin in Dahl salt-resistant and salt-sensitive rats on a high salt diet. Can J Physiol Pharmacol 74 (1996) 657-662
28. Ni X.P., Bhargava A., Pearce D., and Humphreys M.H. Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney. Am J Physiol Regulatory Integrative Comp Physiol 290 (2006) R560-R567
29. Ni X.P., Pearce D., Butler A.A., Cone R.D., and Humphreys M.H. Genetic disruption of γ-melanocyte-stimulating hormone signaling leads to salt-sensitive hypertension in the mouse. J Clin Invest 111 (2003) 1251-1258
30. Mayan H., Ni X.P., Almog S., and Humphreys M.H. Suppression of gamma-melanocyte-stimulating hormone secretion is accompanied by salt-sensitive hypertension in the rat. Hypertension 42 (2003) 962-967
31. Ni X.P., and Humphreys M.H. Prevention of salt-induced hypertension by an analog of gamma-melanocyte-stimulating hormone in the rat. Am J Hypertens 20 (2007) 862-865
32. Hruby V.J., Cai M., Cain J.P., Mayorov A.V., Dedek M.M., and Trivedi D. Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptor. Curr Top Med Chem 7 (2007) 1107-1119
33. Graham M., Shutter J.R., Sarmiento U., Sarosi I., and Stark K.L. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 17 (1997) 273-274
34. Shutter J.R., Graham M., Kinsey A.C., Scully S., Lüthy R., and Stark K.L. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 11 (1997) 593-602
35. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278 (1997) 135-138
36. Shen C.P., Wu K.K., Shearman L.P., Camacho R., Tota M.R., Fong T.M., et al. Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol 14 (2002) 607-610
37. Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Tanaka T., Furuta M., et al. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab 86 (2001) 1921-1924
38. Hoggard N., Johnstone A.M., Faber P., Gibney E.R., Elia M., Lobley G., et al. Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation. Clin Endocrinol 61 (2004) 31-39
39. Adan R.A., and van Dijk G. Melanocortin receptors as drug targets for disorders of energy balance. CNS Neurol Disord Drug Targets 5 (2006) 251-261
40. Wikberg J.E., and Mutulis F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat Rev Drug Discov 7 (2008) 307-323
41. Foster A.C., and Chen C. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia. Curr Top Med Chem 7 (2007) 1131-1136
42. Chaki S., and Okubo T. Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders. Curr Top Med Chem 7 (2007) 1145-1151
43. Catania A., Gatti S., Colombo G., and Lipton J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56 (2004) 1-29
44. Wilson B.D., Ollmann M.M., Kang L., Stoffel M., Bell G.I., and Barsh G.S. Structure and function of ASP, the human homolog of the mouse agouti gene. Hum Mol Genet 4 (1995) 223-230
45. Yang Y.K., and Harmon C.M. Recent developments in our understanding of melanocortin system in the regulation of food intake. Obes Rev 4 (2003) 239-248